FDA approves Pfizer and Moderna booster doses, authorizes mix and match for COVID-19 vaccines
Author
Blaire Bryant
Upcoming Events
Related News
Key Takeaways
On October 21, the Centers for Disease Control and Prevention (CDC) endorsed the use of Moderna and Johnson & Johnson booster shots following a recommendation from the Advisory Committee on Immunization Practices’ (ACIP). The endorsement follows the Food and Drug Administration’s (FDA) October 20 announcement approving the emergency use of booster doses for both vaccines.
The CDC also endorsed the use of heterologous (mix and match) COVID-19 vaccine booster shots, following FDA approval based on safety and efficacy data. Eligible individuals will be able to select their booster dose from any of the FDA endorsed or approved COVID-19 vaccines.
Updated guidelines for the use of a COVID-19 vaccine booster dose are as follows:
- Johnson & Johnson COVID-19 vaccine: A single booster dose may be administered at least two months after completion of the single-dose primary regimen to individuals 18 years of age and older.
- Moderna COVID-19 vaccine: A single booster dose may be administered at least six months after completion of the primary series to individuals that are 65 years of age and older, 18 through 64 years of age at high risk of severe COVID-19, or 18 through 64 years of age with frequent institutional or occupational exposure to COVID-19.
- Pfizer-BioNTech COVID-19 vaccine: A single booster dose may be administered at least six months after completion of the primary series to individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.
As key providers of local public health services and frontline service providers for the medically vulnerable, counties have supported over 190 million vaccinations in the U.S. to date and will continue to play an essential role in the administration of COVID-19 vaccines and boosters. For more information on how county health facilities can prepare for the distribution of COVID-19 boosters, see the “Vaccine Booster Readiness Checklist for County Health Facilities” tab in NACo’s COVID-19 Vaccine Distribution Toolkit.
ADDITIONAL RESOURCES
Resource
COVID-19 Vaccine Toolkit for Counties
Related News
U.S. House reintroduces legislation to address the Medicaid Inmate Exclusion Policy with NACo support
Two bipartisan bills aimed at addressing the Medicaid Inmate Exclusion Policy (MIEP) were recently reintroduced in the U.S. House of Representatives.
U.S. House of Representatives re-establishes Bipartisan Mental Health Caucus with NACo support
On May 7, members of the U.S. House of Representatives appointed new leadership to the Bipartisan Mental Health Caucus, reaffirming their commitment to addressing the nation’s mental health crisis through cross-party collaboration. This renewed focus is a welcome development for counties, which serve on the frontlines of the behavioral health system. Bipartisan initiatives like this help elevate mental health as a national priority, support counties in advancing meaningful policy change and strengthen partnerships across all levels of government.
House passes SUPPORT Act reauthorization
On June 4, the U.S. House of Representatives passed the SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R. 2483) by a strong bipartisan vote of 366–57. The bill, which reauthorizes billions of dollars for critical programs that target overdose prevention, now heads to the Senate Committee on Health, Education, Labor and Pensions, where a version of the bill was overwhelmingly advanced with bipartisan support in the 118th Congress.